尼可地尔联合麝香保心丸对冠心病心绞痛患者高敏C反应蛋白及基质金属蛋白酶-9的影响  

作　　者：张洪霞[1] 李文杰[2] 

机构地区：[1]沈阳市第七人民医院,辽宁110003 [2]辽宁中医药大学附属第一医院

出　　处：《当代医学》2016年第5期144-145,共2页Contemporary Medicine

摘　　要：目的观察尼可地尔联合麝香保心丸对冠心病心绞痛患者血清中高敏C反应蛋白(hs-CRP)及基质金属蛋白酶-9(MMP-9)的影响。方法选择60例经确诊为冠心痛心绞痛的患者,分为2组,对照组给予正规西药治疗;治疗组在正规西药治疗的基础上加尼可地尔及麝香保心丸治疗。所有患者均于入院时以及治疗后8周测高敏C反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)。结果治疗组治疗后hs-CRP为(114.99±31.84)mg/L、MMP-9为(188.04±121.01)ng/m L,各项水平明显低于对照组(P<0.05)。结论尼可地尔联合麝香保心丸通过抗炎机制与西药联合对冠心痛心绞痛的治疗具有肯定的疗效。Objective To observe the effect of nicorandil combined with Shexiang Baoxin Pill on coronary heart disease angina pectoris of serum C reactive protein （hs-CRP） and matrix metalloproteinase-9 （MMP-9） effect. Methods 60 cases of hospitalized patients with -12 in the Department of internal medicine in January 2013 were selected. Diagnosed as coronary heart disease and angina pectoris were divided into two groups, the control group was given regular treatment of Western medicine; treatment group given regular western medicine plus nicorandil and musk to guarantee the heart pill treatment. All patients on admission and 8 weeks after treatment test of high sensitive C reactive protein （hs-CRP）, matrix metalloproteinase -9 （MMP-9）. Results After treatment, the hs-CRP was （114.99±31.84）mg/L, MMP-9 was （188.04±121.01）ng/mL, and the levels were significantly lower than those in the control group （P〈0.05）. Conclusion Nicorandil musk protecting heart pill by anti-inflammatory mechanism and Western medicine combined with the crown heartache has a positive role in treatment of angina pectoris.

关 键 词：心绞痛 尼可地尔 麝香保心丸 C反应蛋白 基质金属蛋白酶-9 

分 类 号：R541.4[医药卫生—心血管疾病]